Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

975 - Chemotherapy in cancer patients undergoing hemodialysis: A multicenter study

Date

09 Oct 2016

Session

Poster display

Presenters

Taro Funakoshi

Citation

Annals of Oncology (2016) 27 (6): 497-521. 10.1093/annonc/mdw390

Authors

T. Funakoshi1, T. Horimatsu1, M. Nakamura2, K. Suyama3, T. Mizukami4, S. Arita5, Y. Ozaki6, H. Yasui7, H. Satake8, M. Toyoda9, S. Yazumi10, T. Kirishima11, A. Nozaki12, A. Yoshioka13, T. Matsubara14, M. Yanagita14, S. Fukuhara15, M. Muto1

Author affiliations

  • 1 Therapeutic Oncology, Kyoto University-Graduate school of medicine, 606-8507 - Kyoto/JP
  • 2 Gastroenterology, Sapporo City General Hospital, 060-8604 - Sapporo/JP
  • 3 Cancer Center, Kumamoto Univercity Hospital, Kumamoto/JP
  • 4 Clinical Oncology, St. Marianna University School of Medicine, Kawasaki/JP
  • 5 Comprehensive Clinical Oncology Faculty Of Medical Sciences, Kyusyu University, Fukuoka/JP
  • 6 Medical Oncology, Toranomon Hospital, Tokyo/JP
  • 7 Medical Oncology, Kyoto Medical Center, 612-0861 - Kyoto/JP
  • 8 Medical Oncology, Kobe City Medical Center General Hospital, 650-0047 - Kobe/JP
  • 9 Medical Oncology/hematology, Kobe University Graduate School of Medicine, Kobe/JP
  • 10 Digestive Disease Center, Kitano Hospital, Osaka/JP
  • 11 Gastroenterology, Kyoto City Hospital, 604-8845 - Kyoto/JP
  • 12 Medical Oncology, Kyoto Miniren Chuo Hospital, Kyoto/JP
  • 13 Medical Oncology, Mitsubishi Kyoto Hospital, Kyoto/JP
  • 14 Nephrology, Kyoto University-Graduate school of medicine, Kyoto/JP
  • 15 Healthcare Epidemiology, Kyoto University-Graduate school of medicine, Kyoto/JP
More

Resources

Abstract 975

Background

Cancer is a major cause of death among patients undergoing hemodialysis (HD). However, little is known about the actual clinical practice of chemotherapy in cancer patients undergoing HD. Therefore, we conducted a nationwide questionnaire survey on chemotherapy for HD patients with cancer.

Methods

This retrospective study included patients undergoing HD who were subsequently diagnosed with cancer from January 2010 to December 2012. We reviewed the clinical courses of the patients who underwent chemotherapy. The questionnaires that were sent to 20 institutions, members of the Onconephrology Consortium, consisted of the following sections: (1) patient characteristics; (2) regimen, dosing, and timing of chemotherapy; and (3) outcome.

Results

Overall, 675 patients were registered and the most frequent primary cancer sites were kidney, colorectum, stomach, lung, bladder, liver, breast, and pancreas. Of these patients, 74 received chemotherapy (44 as palliative chemotherapy, 30 as perioperative chemotherapy). The primary causes of renal failure were chronic glomerulonephritis (23 patients) and diabetic nephropathy (17 patients). The most commonly used cytotoxic drugs were fluoropyrimidine (15 patients) and platinum (eight patients), and the dosing and timing of these drugs differed between institutions; however, the dosing of molecular targeting drugs (24 patients) and hormone therapy drugs (15 patients) was consistent. The median survival time of patients undergoing palliative chemotherapy was 13.0 months (0.1–60.3 months). Of these, three patients (6.8%) died from treatment-related causes and eight patients (18%) died of causes other than cancer. A high proportion of the patients who had diabetic nephropathy died of causes other than cancer including two treatment-related causes. Of 30 patients who received perioperative chemotherapy, six (20%) died of causes other than cancer within three years after the initiation of chemotherapy.

Conclusions

Among HD patients with cancer who received chemotherapy, the rates of mortality from causes other than cancer might be high for both palliative and perioperative chemotherapy. The indications for chemotherapy in HD patients, particularly those with diabetes, should be carefully considered.

Clinical trial identification

Legal entity responsible for the study

Kyoto University

Funding

Japanese association of Dialyisis Physicians

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings